a new potential mechanism of statins' diabetogenic action-the alleles associated with lower circulating LDL cholesterol and increased type 2 diabetes risk were also associated with increased body-mass index (0·11 kg/m² higher with the rs17238484-G allele than in controls, 95% CI 0·07-0·14; p=1·77 × 10 -⁷). Consistent with the genetic association, the investigators also described a subtle increase in weight caused by statins in the trial data (0·30 kg higher, 0·18-0·43; p=3·15 × 10 -⁶). Swerdlow and colleagues 1 provide a new angle to the debate about the adverse side-eff ects of statins. They used a genetic approach-mendelian randomisationthat has proven a valuable method to help understand disease mechanisms. 3, 4 Mendelian randomisation is based on a fundamental principle of biology-that inherited DNA sequence variation is randomised during meiosis independently of the environment and disease processes. Mendelian randomisation approaches have been useful in understanding causality of potentially modifi able risk factors for cardiovascular disease. For example, several studies have used common genetic variants near the gene encoding C-reactive protein (CRP) to show that raised high-sensitivity CRP is unlikely to aff ect the risk of heart disease causally. 5 More recently, studies of genetic variants altering circulating HDL cholesterol concentrations have provided evidence that higher total HDL cholesterol concentrations are unlikely to reduce the risk of coronary artery disease, independently of any eff ects on LDL cholesterol or triglycerides. 6, 7 Of more direct relevance to the debate on statins, common genetic variants that alter LDL cholesterol concentrations are also associated with coronary artery disease. 7, 8 The eff ect of common genetic variants is often subtle, but in some instances it provides great potential for improving mechanistic understanding. The genetic variants in the HMGCR gene have small eff ects on circulating LDL cholesterol (0·06 mmol/L) compared with other variants, which alter LDL concentrations by up to 0·36 mmol/L. Yet the variants in HMGCR provide proof of principle that genetics can be used to identify therapeutic targets.
Swerdlow and colleagues 1 used their own set of 26 236 cases and 164 021 controls as well as those from published studies. The results provide an important addition to a cascade of evidence that suggests a slight on-target type 2 diabetes side-eff ect of statins (fi gure). This cascade includes individual randomised controlled trials that provided some evidence of causality, although the diff erent statins and defi nitions of diabetes used made results hard to interpret. 9, 10 Observational associations between increased statin use and higher incidence of type 2 diabetes were consistent with the early trial data, but were probably heavily confounded by obesity and other factors. 10 Meta-analyses of randomised controlled trials followed 12 with, for example, an analysis of ten trials 11 showing an increased risk of type 2 diabetes. An analysis of intensive-dose versus moderate-dose statin treat ment showed a doseresponse eff ect, with individuals randomly assigned to intensive-dose treatment having a relative risk of 1·12 (95% CI 1·04-1·22) for diabetes compared with individuals assigned to moderate-dose treatment. 13 However, none of these studies could establish whether or not the diabetogenic eff ect of statins operated through the same pathway as the lipid-lowering HMGCoA-reductase eff ect or an off -target eff ect. Swerdlow and colleagues 1 answer this question-because the genetic variant lies near HMGCR, the diabetogenic eff ect of statins probably operates through the same mechanism as the lipidlowering eff ect. The fi ndings imply that new types of statin that more specifi cally target HMGCoA-reductase would not reduce the adverse side-eff ect of increased risk of type 2 diabetes. Evidence of a causal effect of statins on type 2 diabetes risk. Caveat: results differed-some were positive, some negative, and some null. 10 2. Observational epidemiology. Incidence of type 2 diabetes increased as statin use increased. Caveat: there were several sources of confounding and bias. The UK has the second highest rate of tuberculosis among western European countries. 1 Tuberculosis clinics in London manage more cases a year than those in all other western European capital cities put together. Rates of tuberculosis are now nearly fi ve times higher in the UK than in the USA. 2 Lack of progress with tuberculosis control in the UK does not just represent a risk to domestic public health, 3 but also an international embarrassment with examples of cases acquired in the UK leading to infections in other low-incidence countries. In recognition of this unacceptable trend, Public Health England has led a coalition of stakeholders to develop a forum, the national Tuberculosis Oversight Group, where innovation and good practice are shared between local, regional, and national health leaders. These discussions have led to local changes, with several areas establishing tuberculosis control boards and systematic cohort review, and the identifi cation of tuberculosis as a major priority for Public Health England. However, the implementation of improved tuberculosis control measures has not been universal, and there is still unacceptable variation in the quality of clinical and public health measures across England.
A collaborative strategy to tackle tuberculosis in England
There are some limitations to the study. 1 First, the subtle eff ects of the HMGCR variants meant that the investigators had to use large numbers of cases and controls, and the associations between the variants and type 2 diabetes are not statistically beyond reproach-more cases and controls would help confi rm the fi ndings. Second, we cannot be certain that the variants operate directly and solely through the HMGCR gene, although there is some evidence that these variants alter splicing of HMGCR transcripts. 14 Finally, genetic studies are not completely exempt from the confounders and biases of epidemiological studies-survival and index event biases can aff ect genetic studies, and further work with larger numbers of incident cases would provide more reassurance that the genetic associations with type 2 diabetes are real. However, the associations with body-mass index seem to be statistically robust and provide a mechanism downstream of the HMGCoA-reductase eff ect (increased body-mass index leading to increased insulin resistance, and to increased diabetes).
In summary, Swerdlow and colleagues 1 have used naturally occurring human genetic variation to provide another piece of evidence about the side-eff ects of statins, but have not cast any doubt on the evidence that the benefi ts of statins vastly outweigh their risks. 
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